ACI — Albertsons Companies, Inc.

Summary of ACI Q2 2025 Earnings Call

1. Key Financial Results and Metrics:

• Adjusted Identical Sales Growth: 2.2% for Q2 2025.
• Adjusted EBITDA: $848 million.
• Earnings Per Share (EPS): $0.44, in line with expectations.
• Digital Sales Growth: 23% year-over-year, maintaining a compounded annual growth rate (CAGR) of 24% over the last three years.
• Pharmacy Sales Growth: 19% year-over-year, driven by GLP-1 medications and market share gains from competitor closures.
• Gross Margin: 27%, with a year-over-year decrease of 63 basis points, primarily due to a shift towards digital and pharmacy sales.
• Share Repurchase Program: Announced a $750 million accelerated share repurchase, increasing total authorization to $2.75 billion.

2. Strategic Updates and Business Highlights:

• Customer Engagement: Enhanced loyalty program with membership growth of 13% to over 48 million members, driving increased transaction frequency.
• Digital and E-commerce Initiatives: Continued investment in technology and AI, including the launch of the "Ask AI" feature in the mobile app to enhance customer experience.
• Real Estate Portfolio: Valued at $14.3 billion, providing operational advantages and supporting long-term growth.
• Store Closures and Openings: 29 store closures announced year-to-date, with plans to open 9 new stores by year-end.
• Productivity Initiatives: Targeting $1.5 billion in savings from productivity improvements through fiscal 2027.

3. Forward Guidance and Outlook:

• Fiscal 2025 Guidance Update:
  • Identical Sales Range: Increased lower end to 2.2% - 2.75%, driven by pharmacy and digital growth.
  • Adjusted EBITDA: Expected to remain in the range of $3.8 billion to $3.9 billion.
  • Adjusted EPS: Increased to a range of $2.06 to $2.19, reflecting share repurchase impacts.
  • Capital Expenditures: Expected to be between $1.8 billion and $1.9 billion, with a focus on digital and automation investments.

4. Challenges and Points of Concern:

• Gross Margin Pressure: Continued mix shift towards lower-margin pharmacy and digital sales impacting overall gross margin.
• Consumer Behavior: Observed a shift towards value-seeking behaviors, with customers trading down and focusing on promotions and own brands.
• Competitive Pressures: Increased pricing competition noted, with management emphasizing a surgical approach to pricing investments to maintain margins.
• Labor Disputes: A three-week labor dispute in Colorado negatively impacted identical sales by 12 basis points.

5. Notable Q&A Insights:

• Confidence in Growth: Management expressed confidence in returning to long-term growth algorithms in fiscal 2026, driven by strategic priorities and productivity initiatives.
• Pharmacy and E-commerce Dynamics: Pharmacy growth is expected to drive higher comps in Q3, with e-commerce nearing breakeven profitability.
• Pricing Strategy: Management reassured that pricing investments are measured and surgical, aimed at offsetting inflation while enhancing customer value through loyalty programs.
• Asset Management: Discussion on evaluating non-core assets and potential banner consolidation to optimize market presence and performance.

Overall, Albertsons Companies, Inc. demonstrated solid financial performance in Q2 2025, with strategic initiatives focused on enhancing customer engagement, leveraging technology, and improving productivity. However, challenges remain in margin pressures and competitive dynamics, which the company is addressing through targeted strategies.